Plain-English translation of NCT06855056 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
The PROSPECT study is testing whether new biomarkers—special markers found in blood samples—can help doctors predict how well patients with decompensated cirrhosis will do after leaving the hospital. Researchers will collect blood samples and follow patients for 6 months to see if these new markers can identify which patients are at higher risk for serious complications or death.
Right now, doctors don't have reliable ways to predict which cirrhosis patients will do well after hospitalization and which ones will get worse. Finding these new blood markers could help doctors personalize treatment and catch problems early, potentially saving lives.
You likely qualify if…
You likely don't qualify if…
You will be enrolled in the study just before leaving the hospital after your hospitalization. At the first visit, doctors will collect blood samples and measure clinical information. You will then have two follow-up visits over the next 6 months—these can be done in person or by phone—where researchers will ask about your health and collect basic information. The study lasts 180 days total, and your blood samples will be analyzed for special markers that might predict your recovery.
AI-generated summary from trial data · Jul 20, 2026 · Not medical advice
France
Germany
Italy